Antiparkinsonmidler

Barbara S, Connolly MD, Anthony E. Lang MD: Pharmacological Treatment of Parkinson Disease, A Review. JAMA, 2014:311(16):1670-1683. doi:10.1001/jama.2014,3654

Müller T, Przuntek H, Kuhlmann A: Loss of color vision during long-term treatment with pramipexole. J Neurol (2003) 250: 101-102, doi: 10.1007/s00415-003-0915-5

Antiepileptika

Brodtkorb E, Reimers A. Seizure control and pharmacokinetics of antiepileptic drugs in pregnant women with epilepsy. Seizure 2008;17:160-5

Westin AA, Nakken KO, Johannessen SI, Reimers A, Lillestølen KM, Brodtkorb E. Serum concentration/dose ratio of topiramate during pregnancy. Epilepsia 2009;50:480-5

Berg AT et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010 Apr;51(4):676-85

Berg AT, Cross JH. Towards a modern classification of the epilepsies? Lancet Neurol. 2010 May;9(5):459-61

Antiepileptika, veiledende dosering

Reimers A, Berg JA, Burns ML, Landmark CJ. Felles referanseområder for antiepileptika. Tidsskr Nor Laegeforen. 2017 Jun 26;137(12-13):864-865

Benzodiazepiner

Retningslinjer for fylkesmennene ved behandling av førerkortsaker. helsedirektoratet 2013 (IS-2070)

Brivaracetam

Klitgaard H, Matagne A, Nicolas JM, Gillard M, Lamberty Y, De Ryck M, Kaminski RM, Leclercq K, Niespodziany I, Wolff C, Wood M, Hannestad J, Kervyn S, Kenda B. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment. Epilepsia. 2016 Apr;57(4):538-48.

Nicolas JM, Hannestad J, Holden D, Kervyn S, Nabulsi N, Tytgat D, Huang Y, Chanteux H, Staelens L, Matagne A, Mathy FX, Mercier J, Stockis A, Carson RE, Klitgaard H. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia. 2016 Feb;57(2):201-9

Klein P, Tyrlikova I, Brazdil M, Rektor I. Brivaracetam for the treatment of epilepsy. Expert Opin Pharmacother. 2016 Feb;17(2):283-95

Eslikarbazepin

Verrotti A, Loiacono G, Rossi A, Zaccara G. Eslicarbazepine acetate: an update on efficacy and safety in epilepsy Epilepsy Res 2014;108:1-10

Svendsen T, Brodtkorb E, Reimers A, Molden E, Sætre E, Johannessen SI, Johannessen Landmark C. Pharmacokinetic variability, efficacy and tolerability of eslicarbazepine acetate-A national approach to the evaluation of therapeutic drug moni-toring data and clinical outcome. Epilepsy Res. 2017;129:125-131

Dopaminagonister

Thomas J, Moore A B, Glenmullen J, Mattison D R: Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med online oktober 2014

Weiss H D, Pontone G M: Dopamine receptor agonist drugs and impulse control disorders. JAMA Internal Medicine; desember 2014, Vol 174 Nr. 12, 1935-37

Etosuksimid

Glauser TA et al. Ethosuximide, valproic acid and lamotrigine in childhood absence epilepsy. N Engl J Med 2010;362:790-9

Guanfacin

Omtale Intuniv http://pro.medicin.dk/praeparater/7974 (25.01.2016)

EMA EPAR Intuniv (25.01.2016)

Intuniv: Highlights of prescribing information, Shire, (25.01.2016)

EU godkjenner Intuniv for ADHD, www.helseinfonett.no (25.01.2016)

Klobazam

Ng YT et al. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology 2011;77:1473-81

Retningslinjer for fylkesmennene ved behandling av førerkortsaker. helsedirektoratet 2013 (IS-2070)

Klonazepam

Retningslinjer for fylkesmennene ved behandling av førerkortsaker. helsedirektoratet 2013 (IS-2070)

Lakosamid

Halford JJ, Lapointe M. Clinical perspectives on lacosamide. Epilepsy Currents 2009;9:1-9

Ben-Menachem E. Lacosamide: an investigational drug for adjunctive treatment of partial onset seizures. Drugs Today 2008;44:35-40

Rauck RL, Shaibani A, Biton V, Simpson J, Koch B. Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled study. Clin J Pain. 2007;23:150-8

Midler ved hyperkinetisk forstyrrelse og narkolepsi

Bolea-Alamanac B, Nutt DJ, Adamou M, et al. Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorders: Update on recommendations from the British Association for Psychopharmacology. J Psychopharm 2014, Vol 28 (3) 179-203.

ADHD/hyperkinetisk forstyrrelse – nasjonal faglig retningslinje for utredning, behandling og oppfølging Rett diagnose – individuell behandling. Helsedirektoratet Desember 2014 Bestillingsnummer: IS-2060 ISBN-nr. 978-82-8081-283-4

Graham J, Banaschewski T et al. European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry 2011;20:17-37.

Nasjonal faglig retningslinje for utredning, behandling og oppfølging av personer med samtidig ruslidelse og psykisk lidelse - ROP-lidelser (IS-1948).

Perampanel

Franco V, Crema F, Iudice A, Zaccara G, Grillo E. Novel treatment options for epilepsy: Focus on perampanel. Pharmacol Res. 2013 Jan 1;70(1):35-40.lacosamide. Epilepsy Currents 2009;9:1-9

Löscher W, Schmidt D. Epilepsy: perampanel-new promise for refractory epilepsy? Nat Rev Neurol. 2012 Dec;8(12):661-2.

Rektor I. Perampanel , a novel, non-competitive, selective AMPA receptor antagonist as adjunctive therapy for treatment-resistant partial-onset seizures. Expert Opin Pharmacother. 2013 Feb;14(2):225-35.

Retigabin

Brodie M et al. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology 2010;75:1-8

Czuczwar P. Retigabine: The newer potensial antiepileptic drug. Pharmakol rep 2010;62:211-19

Faught E. Ezogabine: A new angle on potassium gates. Epilepsy Curr 2011;11:75-81

Gunthorpe MJ, Large CH, Sankar R. The mecanism of action of retigabine (ezogabine) a first class K⁺ channel opener for the treatment of epilepsy. Epilepsia 2012;53: 412-24

Harden C. Ezogabine AKA retigabine: Is more better? Trying to find the right dose from clinical trials. Epilepsy Curr 2012;12:27-8

Rejdak R et al. Clinical utility of adjunctive retigabine in partial onset seizures. Ther Clin Risk Manag 2012;8:7-14

http://www.docguide.com/anti-seizure-drug-ezogabine-linked-retinal-abnormalities-and-blue-skin-discoloration?tsid=5

Clark S, Antell A, Kaufman K. New antiepileptic medication linked to blue discoloration of the skin and eyes. Ther Adv Drug Saf 2015;6:15-9.

Stiripentol

Chiron C et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled study. Lancet 2000;356:1638-42

Quilichini PP et al. Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-A receptor channels. Epilepsia 2006;47:704-16

Chiron C. Stiripentol. Neurotherapeutics 2007;4:123-5

Fisher JL. The anticonvulsant stiripentol acts directly on the GABA(A) receptor as a positive allorestic modulator. Neuropharmacology 2009;56:190-7

Valproat

Lindbom U et al. Reversibelt demensliknande tillstånd och parkinsonism hos äldre kvinna. Idiosynkratiska biverkningar kopplas til 11 års antiepileptisk medicinering. Läkartidningen 2009;106:863-5

Tomson T, Marson A, Boon P, Canevini MP, Covanis A, Gaily E, Kälviäinen R, Trinka E. Valproate in the treatment of epilepsy in women and girls. Recommendations from a joint Task Force of ILAE-Commission on European Affairs and European Academy of Neurology (EAN). Epilepsia. 2015 Apr 8. doi: 10.1111/epi.13021. [Epub ahead of print]

Vigabatrin

Westall CA, Wright T, Cortese F, Kumarappah A, Snead OC 3rd, Buncic JR.Vigabatrin retinal toxicity in children with infantile spasms: An observational cohort study. Neurology. 2014 Dec 9;83(24):2262-8.